These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 28245034)

  • 1. [Biological treatments in pediatric IBD].
    Svensson M; Lindberg E; Ludvigsson JF
    Lakartidningen; 2017 Feb; 114():. PubMed ID: 28245034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of infliximab and other biologic agents in the inflammatory bowel diseases.
    Reddy JG; Loftus EV
    Gastroenterol Clin North Am; 2006 Dec; 35(4):837-55. PubMed ID: 17129816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour necrosis factor antagonists and inflammatory bowel diseases: a national practice survey.
    Oussalah A; Roblin X; Laharie D; Filippi J; Flamant M; Faure P; Phelip JM; Bigard MA; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2009 Oct; 30(8):854-63. PubMed ID: 19764940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update.
    Leso V; Leggio L; Armuzzi A; Gasbarrini G; Gasbarrini A; Addolorato G
    Eur J Gastroenterol Hepatol; 2010 Jul; 22(7):779-86. PubMed ID: 19786877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases.
    Guerra I; Algaba A; Pérez-Calle JL; Chaparro M; Marín-Jiménez I; García-Castellanos R; González-Lama Y; López-Sanromán A; Manceñido N; Martínez-Montiel P; Quintanilla E; Taxonera C; Villafruela M; Romero-Maté A; López-Serrano P; Gisbert JP; Bermejo F
    J Crohns Colitis; 2012 Jun; 6(5):518-23. PubMed ID: 22398059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TNF antagonists in the treatment of inflammatory bowel disease: results of a survey of gastroenterologists in the French region of Lorraine.
    Peyrin-Biroulet L; Oussalah A; Boucekkine T; Bigard MA
    Gastroenterol Clin Biol; 2009 Jan; 33(1 Pt 1):23-30. PubMed ID: 19118965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of Anti-drug Antibodies to Biologic Medications in Children With Inflammatory Bowel Disease.
    Cohen RZ; Schoen BT; Kugathasan S; Sauer CG
    J Pediatr Gastroenterol Nutr; 2019 Nov; 69(5):551-556. PubMed ID: 31335833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with biologic therapies and the risk of cancer in patients with IBD.
    Biancone L; Calabrese E; Petruzziello C; Pallone F
    Nat Clin Pract Gastroenterol Hepatol; 2007 Feb; 4(2):78-91. PubMed ID: 17268543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How are thiopurines used and monitored by Swedish gastroenterologists when treating patients with inflammatory bowel disease?
    Hindorf U; Andersson P
    Scand J Gastroenterol; 2011 Oct; 46(10):1215-21. PubMed ID: 21793634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease.
    Shivaji UN; Sharratt CL; Thomas T; Smith SCL; Iacucci M; Moran GW; Ghosh S; Bhala N
    Aliment Pharmacol Ther; 2019 Mar; 49(6):664-680. PubMed ID: 30735257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.
    Afzali A; Wheat CL; Hu JK; Olerud JE; Lee SD
    J Crohns Colitis; 2014 Jun; 8(6):480-8. PubMed ID: 24268978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series.
    Sandhu A; Alameel T; Dale CH; Levstik M; Chande N
    Aliment Pharmacol Ther; 2012 Jul; 36(2):159-65. PubMed ID: 22616981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents.
    Braun J; Baraliakos X; Listing J; Davis J; van der Heijde D; Haibel H; Rudwaleit M; Sieper J
    Arthritis Rheum; 2007 May; 57(4):639-47. PubMed ID: 17471540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infliximab therapy for patients with inflammatory bowel disease: 10 years on.
    Van Assche G; Vermeire S; Rutgeerts P
    Eur J Pharmacol; 2009 Nov; 623 Suppl 1():S17-25. PubMed ID: 19837056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease.
    Mocci G; Marzo M; Papa A; Armuzzi A; Guidi L
    J Crohns Colitis; 2013 Nov; 7(10):769-79. PubMed ID: 23453887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure.
    Zelinkova Z; van der Ent C; Bruin KF; van Baalen O; Vermeulen HG; Smalbraak HJ; Ouwendijk RJ; Hoek AC; van der Werf SD; Kuipers EJ; van der Woude CJ;
    Clin Gastroenterol Hepatol; 2013 Mar; 11(3):318-21. PubMed ID: 23103819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between Genetic Polymorphisms and Response to Anti-TNFs in Patients with Inflammatory Bowel Disease.
    Prieto-Pérez R; Almoguera B; Cabaleiro T; Hakonarson H; Abad-Santos F
    Int J Mol Sci; 2016 Feb; 17(2):225. PubMed ID: 26861312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort.
    Bálint A; Rutka M; Végh Z; Kürti Z; Gecse KB; Banai J; Bene L; Gasztonyi B; Kristóf T; Lakatos L; Miheller P; Palatka K; Patai Á; Salamon Á; Szamosi T; Szepes Z; Tóth GT; Vincze Á; Bor R; Milassin Á; Fábián A; Nagy F; Kolar M; Bortlik M; Duricova D; Hruba V; Lukas M; Mitrova K; Malickova K; Lukas M; Lakatos PL; Molnár T; Farkas K
    Expert Opin Drug Saf; 2017 Aug; 16(8):885-890. PubMed ID: 28504555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral Lichen Planus in IBD Patients: A Paradoxical Adverse Effect of Anti-TNF-α Therapy.
    Andrade P; Lopes S; Albuquerque A; Osório F; Pardal J; Macedo G
    Dig Dis Sci; 2015 Sep; 60(9):2746-9. PubMed ID: 25917051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.